New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has directed Abbott Healthcare Pvt. Ltd. to submit the proposed prescribing information (PI) and relevant literature or supporting data for Triamcinolone Hexacetonide Injectable Suspension USP 40 mg/2 ml (Pre-filled syringe).

The directive was issued after a detailed review of the company’s proposal during the SEC meeting held on September 17, 2025, at CDSCO headquarters in New Delhi.

During the meeting, Abbott presented its proposal for introducing Triamcinolone Hexacetonide Injectable Suspension USP 40 mg/2 ml Pre-filled Syringe (Single Dose) for use in already approved indications. The firm also submitted a detailed justification of the rationale and clinical need for this new

See Full Page